发表一篇学和医学成像类SCI论文
需要多少钱?
The efficacy and safety of immunotherapy targeting the PD-1 pathway for advanced urothelial carcinoma: a meta-analysis of published clinical trials
切换为中文
Abstract:
Introduction Urothelial carcinoma (UC) is an aggressive malignancy and has a poor prognosis in the metastatic state. Treatment of UC remains a challenge, and as a first-line regimen for advanced UC, standard platinum-based chemotherapy is unfit for many patients due to numerous comorbidities and poor performance status. Recently, five immune checkpoint inhibitors have been approved for the treatment of patients with advanced UC who were ineligible for platinum-based regimens or suffered tumor progression in post-platinum setting. However, not long ago, the U.S. Food and Drug Administration restricted the use of two common immune checkpoint blockades, atezolizumab and pembrolizumab, due to uncertain survival benefit as mono-therapy. In this scenario, we reviewed rapidly surfacing clinical trials to assess the efficacy and safety of immunotherapy targeting the PD-1 pathway for advanced UC. Methods A comprehensive search was conducted in PubMed, EMBASE and Cochrane Library for all clinical trials where the efficacy and safety were reported. Our primary outcome was efficacy evaluated by objective response rate (ORR), 1-year overall survival (OS) rate and 1-year progression-free survival (PFS) rate, and second outcome was safety assessed by any grade and grade 3–4 treatment-related adverse events (TRAEs). We chose percentages with 95% confidence intervals (CI) as the evaluation indexes and used a random-effects model to account for heterogeneity. Results We included 14 clinical trials with 2674 total patients in this meta-analysis. After removing unqualified studies on the basis of sensitivity analyses, 13 studies were pooled to evaluate the overall ORR, 8 studies for the 1-year OS rate and 6 studies for the 1-year PFS rate. The pooled data of ORR, 1-year OS rate, and 1-year PFS rate were 0.20 (95% CI 0.18–0.22, I ^2 = 38.4%, P = 0.078), 0.50 (95% CI 0.46–0.53, I ^2 = 30.3%, P = 0.186), and 0.17 (95% CI 0.14–0.20, I ^2 = 0.0%, P = 0.668), respectively. Similarly, 13 trials were utilized to compute the pooled rate of any-grade TRAEs. The pooled estimation of any-grade was 0.65 (95% CI 0.63–0.67, I ^2 = 1.7%, P = 0.429). The pooled rate of grade 3–4 TRAEs subgroups with Atezolizumab, Pembrolizumab, Durvalumab, Nivolumab and Avelumab were 0.11 (95% CI 0.06–0.15, I ^2 = 83.5%, P = 0.000), 0.15 (95% CI 0.13–0.18, I ^2 = 0.0%, P = 0.971), 0.06 (95% CI 0.03–0.09, I ^2 = 0.0%, P = 0.566), 0.19 (95% CI 0.15–0.23, I ^2 = 0.0%, P = 0.480) and 0.08 (95% CI 0.05–0.11, I ^2 = 0.0%, P = 0.702), respectively. Conclusion This study showed that the immunotherapy targeting the PD-1 pathway had durable efficacy and acceptable safety in patients with advanced UC. The comprehensive role of immune checkpoint inhibitors in comparison to other treatments needs further confirmation basing on RCTs.
展开更多
Clinical & Translational Oncology
CLIN TRANSL ONCOL
| 最新影响因子：3.34 | 期刊ISSN：1699-048X | CiteScore：5.16 |
| 出版周期：Monthly | 是否OA：YES | 出版年份：2005 |
| 自引率：2.20% | 研究方向：医学-肿瘤学 |
| 出版地区：SPAIN |
SCI期刊coverage：Science Citation Index Expanded（科学引文索引扩展）
专业编辑在线一对一答疑及时解决您的问题
Clinical & Translational Oncology 期刊简介
英文简介：
Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of biomarkers for cancer diagnosis, prognosis or prediction of treatment response, identification of new targets for cancer therapy, as well as development of new technologies for research and treatment of cancer are the major themes covered by both the educational series and research articles. A broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.
中文简介：（来自Google、百度翻译）
《临床与转化肿瘤学》是一本致力于促进实验肿瘤学与临床肿瘤学相互作用的国际期刊。它涵盖了癌症研究的所有方面，从涉及肿瘤细胞和分子生物学的更基本的发现，到最先进的传统和新药的临床检测。此外，该杂志致力于促进从基础实验室到临床实践的知识转移，出版了一系列致力于缩小分子肿瘤学家和临床肿瘤学家之间差距的教育系列。肿瘤分子生物学、癌症诊断生物标记物的识别、治疗反应的预后或预测、癌症治疗新靶点的识别以及癌症研究和治疗新技术的开发是教育系列和研究文章的主题。将考虑发表广泛的主题，包括疾病的分子和细胞基础、病因学、病理生理学、病理学、流行病学、临床特征以及癌症的诊断、预后和治疗。
申请加急绿色通道，投稿周期比同行快2-3个月 现在咨询
Clinical & Translational Oncology 期刊中科院评价数据
最新中科院分区
| 大类(学科) | 小类(学科) | 学科排名 |
| 医学 |
ONCOLOGY (肿瘤学) 4区 |
156/223 |
最新公布的期刊年发文量
| 年度总发文量 | 年度论文发表量 | 年度综述发表量 |
| 179 | 144 | 35 |
总被引频次：2572
特征因子：0.004620
影响因子趋势图
无法辨别期刊质量？专业编辑老师一对一讲解，现在咨询现在咨询
Clinical & Translational Oncology 期刊CiteScore评价数据
最新CiteScore值
5.16
=
引文计数(2018)
文献(2015-2017)
=
8579次引用
1661篇文献
文献总数（2014-2016）：1661
被引比率：73%
SJR：3.788
SCLmago期刊等级衡量经过加权后的期刊受引用次数，引用次数的加权值由施引期刊的学科领域和声望(SJR)决定。
SNIP：2.396
每篇文章中来源出版物的标准化影响将实际受引用情况对照期刊所属学科领域中预期的受引用情况进行衡量。
CiteScore排名
| 序号 | 类别 | 排名 | 百分位 |
| 1 |
大类(学科)：Medicine
小类(学科)：Pulmonary and Respiratory Medicine
|
#4/132
点击查看排名表
|
|
CiteScore趋势图
Scopus涵盖范围
无法辨别期刊质量？专业编辑老师一对一讲解，现在咨询现在咨询
Clinical & Translational Oncology 期刊常见问题
热门常见问题
无法辨别期刊质量？专业编辑老师一对一讲解，现在咨询现在咨询
权益保障
-
刊物信息可查
推荐刊物均可到国家新闻出
版总署网站查询正刊 -
严格保密协协议
可签署保密协议 ，不透露任
何用户信息可跟踪进程，全程
协议 -
售后服务保障
1对1服务，7x24小时在线
-
企业信誉保障
14年经验沉淀，实体公司
运营
最新评论(不代表本站观点)
-
liting7111
研究方向：肿瘤 癌症
审稿时间： 2个月内
14年10月17日投稿，15年2月2日接受，期间小修一次，小修回去一个月才接受，审稿人意见也很nice，小修投回去好像还外审了一次。2020-05-26 -
liting7111
研究方向：肿瘤 癌症
投了三个月，前两个月，一直在分配审稿人，后一个月接收了，大致也就是两到三个月，建议投稿需要临床结合基础比较稳妥。2020-05-04 -
liting7111
研究方向：肿瘤 癌症
审稿时间： 2个月内 接受率： 中等（50%命中）
我投的一篇综述，中了，另外一篇秒拒。在4月19号投稿，到6月15号接受。大修一次，修回第二天邮件通知接收，开始进行proof和版权转让事宜。2020-04-25 -
liting7111
文章刚接收，这里的评论对我帮助挺大，给大家分享下我的投稿经过。投稿到接受花了三个月时间，reviewers给的意见也专业中肯。投稿，修改，投回接收花了不到两周，如果赶着毕业的话，选择这本期刊是个不错的选择。2020-04-16 -
liting7111
研究方向：meta
审稿时间： 2个月内 接受率： 比较困难（25%命中）
稿件处理速度很快，审的也快，投稿后审了两个月，拒稿。2020-03-01 -
liting7111
审稿时间： 2个月内 接受率： 中等（50%命中）
刚收到接收函，速度挺快一个月时间。感觉杂志投稿的人不多，可能这样速度才快的吧。2020-02-06
相关期刊
-
Mechanics of Solids...
影响因子：0.549
ISSN：0025-6544
研究方向：医学-力学
-
GEOPHYSICAL AND ASTROPHYSICAL FLUID DYNAMICS...
影响因子：1.59
ISSN：0309-1929
研究方向：地学天文-地球化学与地球物理
-
SOUND AND VIBRATION...
影响因子：0
ISSN：1541-0161
研究方向：物理-工程：机械
-
JOURNAL OF SOUND AND VIBRATION...
影响因子：4.761
ISSN：0022-460X
研究方向：工程技术-工程：机械
-
JOURNAL OF VIBRATION AND CONTROL...
影响因子：2.633
ISSN：1077-5463
研究方向：工程技术-工程：机械
-
International Journal of Aeroacoustics...
影响因子：2.04
ISSN：1475-472X
研究方向：ACOUSTICS-ENGINEERING, AEROSPACE
-
International Journal of Acoustics and Vibration...
影响因子：0.632
ISSN：1027-5851
研究方向：ACOUSTICS-ENGINEERING, MECHANICAL
-
JOURNAL OF VIBRATION AND ACOUSTICS-TRANSACTIONS OF THE ASME...
影响因子：1.701
ISSN：1048-9002
研究方向：工程技术-工程：机械
-
JOURNAL OF ADHESION...
影响因子：2.446
ISSN：0021-8464
研究方向：工程技术-材料科学：综合
Clinical & Translational Oncology 投稿经验
(由下方点评分析获得，6人参与，31827人阅读）